168 related articles for article (PubMed ID: 17405746)
1. Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly.
Berrebi A; Feldberg E; Spivak I; Shvidel L
Haematologica; 2007 Feb; 92(2):e15-6. PubMed ID: 17405746
[TBL] [Abstract][Full Text] [Related]
2. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
Duan M; Zhou D
Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
[No Abstract] [Full Text] [Related]
3. Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia.
Pozzato G; Zorat F; Nascimben F; Comar C; Kikic F; Festini G
Haematologica; 2001 Jul; 86(7):772-3. PubMed ID: 11454539
[No Abstract] [Full Text] [Related]
4. Current treatment of myelofibrosis.
Silver R
Clin Adv Hematol Oncol; 2005 Apr; 3(4):269-70. PubMed ID: 16166999
[No Abstract] [Full Text] [Related]
5. Thalidomide treatment in a myelofibrosis patient with leukemia transformation.
Huang WH; Li MS; Chu SC; Wang TF; Kao RH; Wu YF
Int J Hematol; 2014 Feb; 99(2):188-92. PubMed ID: 24307514
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder G; Reeder T; Zeldis JB; Tefferi A
Blood; 2003 Apr; 101(7):2534-41. PubMed ID: 12517815
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide and lenalidomide in primary myelofibrosis.
Holle N; de Witte T; Mandigers C; Schaap N; Raymakers R
Neth J Med; 2010 Aug; 68(1):293-8. PubMed ID: 20739725
[TBL] [Abstract][Full Text] [Related]
8. Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide.
Strupp C; Fenk R; Kündgen A; Gattermann N; Haas R; Germing U
Leuk Res; 2005 Aug; 29(8):967-9. PubMed ID: 15978949
[TBL] [Abstract][Full Text] [Related]
9. Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone.
Bělohlávková P; Maisnar V; Voglová J; Buchler T; Žák P
Acta Medica (Hradec Kralove); 2016; 59(2):50-3. PubMed ID: 27526305
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
[TBL] [Abstract][Full Text] [Related]
11. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.
Mesa RA; Elliott MA; Schroeder G; Tefferi A
Mayo Clin Proc; 2004 Jul; 79(7):883-9. PubMed ID: 15244384
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.
Arora B; Mesa R; Tefferi A
Leuk Lymphoma; 2004 Dec; 45(12):2373-86. PubMed ID: 15621750
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.
Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S
Leukemia; 2002 Sep; 16(9):1609-14. PubMed ID: 12200671
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.
Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A
Leuk Lymphoma; 2002 Dec; 43(12):2301-7. PubMed ID: 12613516
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous hematologic remission in agnogenic myeloid metaplasia.
Shreiner DP
Am J Med; 1976 Jun; 60(7):1014-8. PubMed ID: 937347
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of combination therapy with low-dose thalidomide plus prednisolone ameliorating cytopenia in primary myelofibrosis.
Hattori Y; Miyakawa Y; Yokoyama K; Yamada T; Du W; Jinzaki M; Shinmoto H; Okamoto S
Int J Hematol; 2011 Jan; 93(1):129-31. PubMed ID: 21153775
[No Abstract] [Full Text] [Related]
17. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
Thapaliya P; Tefferi A; Pardanani A; Steensma DP; Camoriano J; Wu W; Geyer S; Mesa RA
Am J Hematol; 2011 Jan; 86(1):96-8. PubMed ID: 21132732
[TBL] [Abstract][Full Text] [Related]
18. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B
J Clin Oncol; 2004 Feb; 22(3):424-31. PubMed ID: 14752066
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.
Barosi G; Grossi A; Comotti B; Musto P; Gamba G; Marchetti M
Br J Haematol; 2001 Jul; 114(1):78-83. PubMed ID: 11472348
[TBL] [Abstract][Full Text] [Related]
20. Modern management of myelofibrosis.
Cervantes F
Br J Haematol; 2005 Mar; 128(5):583-92. PubMed ID: 15725078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
